EUCTR2004-002644-10-ES进行中（未招募）不适用
A 28-week extension to a multicenter, randomized, double-blind, active controlled study to compare the effect of 24 weeks treatment with LAF237 50 mg bid to rosiglitazone 8 mg qd in drug naïve patients with type 2 diabetesExtensión de 28 semanas del estudio multicéntrico, aleatorizado, doble ciego, con control activo que compara el efecto de 24 semanas de tratamiento con 50 mg bid de LAF237 frente a 8 mg qd de rosiglitazona en pacientes naive con diabetes Tipo 2.
ovartis Farmaceutica S.A.0 个研究点目标入组 660 人开始时间: 2004年12月7日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 660
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Written informed consent to participate in the extension study.
- •Ability to comply with all study requirements.
- •Details of inclusion and exclusion into the core study can be found in the core protocol
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Premature discontinuation from the core study.
- •Concomitant medical conditions that interfere with the interpretation of study results as defined in the core protocol.
- •Failure to comply with the core study protocol.
- •Any patients that the primary investigator decides should not participate in the extension study.
研究者
相似试验
已完成
不适用
30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)-E10 Insulin-dependent diabetes mellitus-E14 Unspecified diabetes mellitusInsulin-dependent diabetes mellitusUnspecified diabetes mellitusE10E14PER-110-07MERCK SHARP & DOHME PERU S.R.L.,
进行中（未招募）
1 期
A 52-week extension to a multicenter, randomized, double-blind, active controlled study to compare the effect of 52 weeks treatment with LAF237 50 mg bid to metformin up to 1000 mg bid in drug naïve patients with type 2 diabetesType II DiabetesEUCTR2004-002136-25-ESovartis Pharma S.A
进行中（未招募）
不适用
A 52-week extension to a multicenter, randomized, double-blind, active controlled study to compare the effect of 52 weeks treatment with LAF237 50 mg bid to metformin up to 1000 mg bid in drug naïve patients with type 2 diabetesEUCTR2004-002136-25-GBovartis Pharmaceuticals UK Ltd530
进行中（未招募）
1 期
A 28-Week Extension to a Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment with LAF237 (50 mg qd or bid) to Placebo as Add-On Therapy in Patients with Type 2 Diabetes Inadequately Controlled with Metformin MonotherapyType 2 DibetesEUCTR2004-002757-31-SEovartis Sverige AB
进行中（未招募）
1 期
A 50 Week Extension to: A Multicenter, Randomized, Double-Blind Factorial Study of the Co-Administration of MK-0431 and Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control - MK-0431 and Metformin Co-Administration Factorial Study in Patients With Type 2 Diabetes MellitusType 2 Diabetes MellitusEUCTR2005-000407-34-GBMerck Sharp & Dohme Limited900